Total-body PET scan using FDA-approved tracers for prostate or NET cancer
Part of Cancer, Kidney & urinary, Skin clinical trials.
This pilot study tests a total-body PET scan with approved tracer medicines to help detect cancer spread in people with suspected metastatic prostate cancer or certain neuroendocrine tumors (NETs). You may be able to join if recent scans already suggest metastasis and you can safely complete the scan timing and positioning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old
- Your most recent scan (CT/MRI/bone scan/fluciclovine or DOTATATE PET/CT) suggests cancer spread and was done within the required time window
- If you have prostate cancer, you’re being checked for suspected metastatic disease
- If you have a NET, your tumor must be somatostatin-receptor positive on a prior DOTATATE PET/CT
- You cannot be pregnant or breastfeeding
- You must be able to lie flat (on your back) for up to 90 minutes at scan timepoints and manage claustrophobia
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
This study is testing a new type of PET scan that uses a special tracer to make tumors easier to see. It may help doctors get more accurate information about your tumor before you have a biopsy or surgery.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
This study tests a new imaging method (PET scan) that uses a special tracer to find prostate cancer cells, whether it's the first diagnosis or a recurrence after treatment. The goal is to see how well this imaging works for locating cancer in the body.
This early-phase study tests special PET/CT scans using a radioactive tracer to see cancer areas that have specific targets. It may help doctors better visualize tumors and plan next steps, using scans that you may already be familiar with (FDG) plus targeted tracers.
This research study tests a new imaging scan (called 68Ga-OncoACP3-PET/CT) to help find prostate cancer and see where it may have spread. The scan uses a radioactive tracer to help doctors visualize cancer cells and decide on the best treatment options.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.